Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback